FDA Announces New Center for Drug Evaluation and Research (CDER) AI Council
Summary
Patrizia Cavazzoni, director of CDER, sent out an all-staff email announcing the creation of a new AI council, which will provide oversight, coordination, and consolidation of AI activities for the drug center. It will also advance innovative uses of AI and help CDER to meet requirements outlined in the Biden Administration’s AI Executive Order 14110 and the Office of Management and Budget’s Memorandum, Advancing Governance, Innovation, and Risk Management for Agency Use of Artificial Intelligence.
Impacted Sectors
© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.